Hello! Welcome to ONTORES!

CN +86-21-68388652

Your shopping cart is empty.

According to the order.

Ordering Center

Peptide therapeutics: current status and future directions

Published: 2017-01-03

Keyword: peptide therapeutics,SWOT, rational design,GLP-1,CPP

Literature:Drug Discovery Today, IF 5.625


Keywords:peptide therapeutics, SWOT, rational design, GLP-1, CPP


Background:Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated. Given that the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design. Examples of such approaches are multifunctional and cell penetrating peptides, as well as peptide drug conjugates. Here, we discuss SWOT analysis of peptides as medicines, and emerging new opportunities in peptide drug design and development.

 

 

Figure 1 Analysis of SWOT of naturally occurring peptides in their use as therapeutics

 

       Conclusions CurrentlyThere are about 60 peptide drugs are proven by FDA, over 140 peptides are during clinical research and around 500 peptides are investigated pre-clinically. Peptide drugs have promising prospects due to their potent and specific, yet safe, mode of action.

 

As a leading Biotech company over world, Ontores committed to provide professionally high quality and comprehensive proteomic and genomic industry solution to our global customers. Ontores offers innovative solutions for antibodies, building blocks, oligonucleotides and peptides and carries a broad spectrum of bio-reagents that will meet everyone’s need in their multi-disciplinary research. Ontores also provides cutting edge custom services including antibody production, contract research services and peptide synthesis.